Superantigen conjugate
OwnerB. Backstrom, Andrea McNeillinventors
Life of this patent
Estimating the term…
Abstract
This invention relates to treatment of multiple sclerosis using an immunomodulatory construct including a T cell binding defective superantigen coupled to one or more myelin-associated proteins, peptides, or functionally equivalent variants thereof.
Claims13
A method for the treatment of multiple sclerosis, the method comprising at the least the step of administering to a subject in need thereof an immunomodulatory construct comprising a T cell binding defective superantigen (mSag) coupled to one or more myelin-associated protein, peptide or functionally equivalent variant thereof.
A method for the treatment of multiple sclerosis, the method comprising at the least the steps of:
- a) collecting and purifying regulatory T cells from a patient with multiple sclerosis;
- b) ex vivo stimulating the T cells with an immunomodulatory construct comprising a T cell binding defective superantigen (mSag) coupled to at least one second myelin-associated protein, peptide or functionally equivalent variant thereof;
- and
- c) administering the stimulated T cells into the patient.
A method of treating multiple sclerosis induced by immune cells to a first myelin-associated protein or peptide, wherein the method includes at least the step of administering to a subject in need thereof an immunomodulatory construct comprising a T cell binding defective superantigen (mSag) coupled to one or more myelin-associated protein, peptide or functionally equivalent variant thereof which is distinct from the first myelin-associated protein or peptide.
An immunomodulatory construct comprising a T cell binding defective superantigen coupled to one or more myelin-associated protein, peptide or functionally equivalent variant thereof.
A pharmaceutical composition comprising an immunomodulatory construct comprising a T cell binding defective superantigen coupled to one or more myelin-associated protein, peptide or functionally equivalent variant thereof in combination with one or more pharmaceutically acceptable carriers, adjuvants, excipients and/or diluents.
A kit for treatment of multiple sclerosis, the kit comprising at least an immunomodulatory construct comprising a T cell binding defective superantigen coupled to one or more myelin-associated protein, peptide or functionally equivalent variant thereof, or a pharmaceutical composition comprising same.
Dependencies are inferred from the claim text.